BELL Stock Overview
Belluscura plc develops and commercialize oxygen related medical device products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Belluscura plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.077 |
52 Week High | UK£0.52 |
52 Week Low | UK£0.07 |
Beta | 0.65 |
1 Month Change | -61.25% |
3 Month Change | -60.76% |
1 Year Change | -80.38% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -85.38% |
Recent News & Updates
Shareholder Returns
BELL | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 3.3% | 2.1% | 2.3% |
1Y | -80.4% | -9.3% | 0.6% |
Return vs Industry: BELL underperformed the UK Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: BELL underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
BELL volatility | |
---|---|
BELL Average Weekly Movement | 18.3% |
Medical Equipment Industry Average Movement | 8.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BELL's share price has been volatile over the past 3 months.
Volatility Over Time: BELL's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 24 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products. The company offers X-PLOR, a modular portable oxygen concentrator. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
BELL fundamental statistics | |
---|---|
Market cap | UK£12.79m |
Earnings (TTM) | -UK£8.02m |
Revenue (TTM) | UK£964.81k |
13.3x
P/S Ratio-1.6x
P/E RatioIs BELL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BELL income statement (TTM) | |
---|---|
Revenue | US$1.20m |
Cost of Revenue | US$314.50k |
Gross Profit | US$888.06k |
Other Expenses | US$10.89m |
Earnings | -US$10.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.061 |
Gross Margin | 73.85% |
Net Profit Margin | -831.70% |
Debt/Equity Ratio | 0.4% |
How did BELL perform over the long term?
See historical performance and comparison